A recent study published on PubMed highlights promising findings in the treatment of depression using intranasal ketamine. Researchers found that racemic ketamine is non-inferior to esketamine, meaning it delivers comparable improvements in depressive symptoms while potentially offering a more cost-effective and accessible option for patients. This is especially important as demand grows for fast-acting alternatives to traditional antidepressants.
At Charleston Ketamine Center, these findings reinforce the value of ketamine-based therapies in real-world clinical care. Intranasal treatment options provide a convenient, minimally invasive approach while maintaining strong therapeutic outcomes. As research continues to evolve, ketamine therapy remains a powerful tool in helping patients achieve meaningful relief from depression and improve overall quality of life.